Dear stakeholders, For information, the company have advised that they do not wish to submit to NICE for this indication at this time. Therefore, NICE has decided to suspend this appraisal from its current work programme.
- Status:
- Suspended
- Technology type:
- Medicine
- Decision:
- Selected
- Prioritisation programme:
- Medicines evaluation
- Rationale:
Criteria within the VPAG met as a new active substance.
- Process:
- STA Standard
- ID number:
- 12279
Project Team
- Project lead
- Danielle Lees
Email enquiries
If you have any queries please email topic.selection@nice.org.uk
Timeline
Key events during the development of the guidance:
| Date | Update |
|---|---|
| 17 February 2026 | Suspended. Dear stakeholders, For information, the company have advised that they do not wish to submit to NICE for this indication at this time. Therefore, NICE has decided to suspend this appraisal from its current work programme. |
| 12 November 2025 | Topic selection |
For further information on our processes and methods, please see our CHTE processes and methods manual